
Opinion|Videos|March 6, 2025
Updates From the RATIONALE-306 Trial
The panelists discuss how the RATIONALE-306 trial demonstrated efficacy outcomes through its design, measuring both progression-free survival and overall survival as key end points.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































